After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.

Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.

A green light would have made Vyglxia the first and only FDA-approved treatment for spinocerebellar ataxia, a life-threatening neurodegenerative disease characterized by progressive loss of voluntary ...

Correspondence to Dr Thiago Junqueira Ribeiro Rezende, Department of Neurology, University of Campinas (UNICAMP), Campinas, SP, Brazil; thiago.jrezende{at}gmail.com Background Spinal cord damage is a ...

Biohaven Ltd. (NYSE:BHVN) stock is trading higher on Friday following an update with respect to its New Drug Application for troriluzole for adult patients with Spinocerebellar Ataxia (SCA). In May ...

Treatment options for age-related macular degeneration (AMD) vary depending on whether you have dry or wet macular degeneration, as well as what stage your condition is in: early, intermediate, or ...

Geographic atrophy (GA) is one of two kinds of advanced age-related macular degeneration (AMD). It’s an eye disease that damages cells in the central part of your retina called the macula. Late-stage ...

An expert discussed the symptoms and outlook for the future for patients with this rare disease Buccaneers' Baker Mayfield Seemingly Takes Shot at Panthers Coach After Win Has Trump left Scotch on the ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing neovascular age-related macular degeneration (nAMD) in older patients with diabetes, ...

Cure Rare Disease (CRD), a clinical-stage nonprofit biotechnology company developing genetic medicines for ultra-rare and rare conditions, today announced that the U.S. Food and Drug Administration ...